Journal: Cells
Article Title: Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma.
doi: 10.3390/cells11213482
Figure Lengend Snippet: Figure 4. Modelling. (A) hLIFR-ID01 complex. The protein backbone is displayed in ribbon and coloured by distinguishing the five domains (D1–D5). In the zoom view, (I) the ID01 binding mode of mifepristone (displayed as yellow ball and stick), highlighting the “T-inverted” shape; (II) the “T-inverted” shape well-fit with hLIFR surface; (III) the main residues involved in the interactions with the mifepristone; (IV) the hydrophobic (yellow) and hydrogen bond acceptor (red) maps fit with mifepristone. The principal residues are labelled and highlighted in wireframe or CPK(A3), while hydrogen bonds are in dashed black lines. (B) Superimposition between the ID01 best MM/GBSA value pose (black) and the mLIFR-hLIF X-ray (PDB ID: 2Q7N) (cyan). The three loops L1 (255-VSASSG-260), L2 (303-NPGRVTALVGPRAT-316), and L3 (332-KRAEAPTNES-341) are highlighted in yellow, blue, and green, respectively. The red rectangle highlights the clash with the propyne moiety of mifepristone and hLIF. (C) Two-dimensional structures of mifepristone. (D) The root means square fluctuation (RMSF) plot of the three compared systems (ID01 complex, hLIFR-hLIF, and hLIFR) during 100 ns of MDs.
Article Snippet: Recombinant human LIFR (His Tag) and biotinylated recombinant human LIF were purchased from Sino Biologicals (Sino Biological Europe GmbH, Dusseldorf, Germany) and R&D Systems (Abingdon, UK), respectively, and both were reconstituted as required by the manufacturer.
Techniques: Binding Assay